Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Insider Sells $91,190.75 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Douglas Kerr sold 3,745 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $24.35, for a total value of $91,190.75. Following the completion of the sale, the insider owned 163,854 shares in the company, valued at $3,989,844.90. The trade was a 2.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Douglas Kerr also recently made the following trade(s):

• On Tuesday, September 8th, Douglas Kerr sold 1,290 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.88, for a total transaction of $24,355.20.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN traded down $3.97 during midday trading on Tuesday, hitting $20.31. 17,067,421 shares of the company’s stock were exchanged, compared to its average volume of 2,151,348. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. The company’s 50 day moving average price is $24.86 and its 200 day moving average price is $20.45. Dyne Therapeutics, Inc. has a 12 month low of $11.92 and a 12 month high of $27.31. The firm has a market capitalization of $3.79 billion, a PE ratio of -6.10 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). As a group, analysts predict that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DYN. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a research note on Friday, May 15th. Sanford C. Bernstein lifted their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Wall Street Zen downgraded shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Morgan Stanley reduced their price target on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Finally, Cantor Fitzgerald started coverage on shares of Dyne Therapeutics in a research note on Thursday, July 23rd. They issued an “overweight” rating for the company. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.17.

Trending Headlines about Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne will present six- and 12-month ACHIEVE data at the World Muscle Society and AANEM meetings on September 30. The presentations will compare a pooled treated group with a matched natural-history cohort and include updated safety information. Topline data from the fully enrolled registrational expansion cohort remain targeted for Q1 2027. Dyne ACHIEVE data announcement
• Positive Sentiment: Z-basivarsen has received FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, while Dyne is advancing the program into the Phase 3 HARMONIA trial. These regulatory designations and upcoming data could provide future catalysts if clinical benefit is confirmed.
• Neutral Sentiment: Options activity was unusually high, with traders purchasing approximately 20,532 call contracts—more than 40 times the average daily call volume. This may reflect speculative positioning ahead of clinical presentations, but it does not establish a fundamental change in the company’s outlook.
• Neutral Sentiment: Several insiders, including CEO John Cox, Chief Medical Officer Douglas Kerr and Chief Commercial Officer Johanna Friedl-Naderer, reported small stock sales. The filings state that the transactions were made to cover tax withholding obligations from vested equity awards, reducing their negative significance.
• Negative Sentiment: Investor sentiment was pressured after a competing DM1 drug reportedly failed in a Phase 3 trial. The result may have increased concern about the difficulty of demonstrating meaningful clinical benefit in DM1 and raised the risk profile ahead of Dyne’s own data release. DM1 rival trial news
• Negative Sentiment: No company-specific negative clinical result was confirmed in the reports. However, the absence of new efficacy data today, combined with uncertainty surrounding the upcoming one-year results and the delay until Q1 2027 for registrational-cohort topline data, left DYN vulnerable to profit-taking and risk reduction. Dyne share decline report

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC bought a new stake in shares of Dyne Therapeutics during the first quarter valued at approximately $26,000. Strs Ohio bought a new position in shares of Dyne Therapeutics in the 4th quarter worth $51,000. Allworth Financial LP bought a new position in shares of Dyne Therapeutics in the 2nd quarter worth $62,000. Aster Capital Management DIFC Ltd acquired a new stake in Dyne Therapeutics in the 4th quarter valued at $84,000. Finally, Steward Partners Investment Advisory LLC grew its position in Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.